The previously mentioned homology with ALK-rearranged lung cancers can, moreover, improve understanding of ROS1-driven NSCLC cases under treatment and drive helpful clinical suggestions [111]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.